Ariel E. Feldstein
Pfizer (United States) · 308 works · 35,184 citations · h-index 83
Top works
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
- Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
- In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease
- Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years
- Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis
- Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis
- NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
- Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
- Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
- From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
- Triggering and resolution of inflammation in NASH
- Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis
- Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
- Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease
- Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal